5 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyChronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, urinary system disorderRecruitingPhase 32026-10-05NCT04557462
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- VFemale Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin and Connective Tissue Diseases, Urination Disorders, Urogenital Diseases, Urological Manifestations, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, proteinuria, systemic lupus erythematosus, urinary system disorderRecruitingPhase 22026-10-01NCT05268289
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorderRecruitingPhase 32026-09-04NCT07517263
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, complement 3 glomerulopathy, proteinuria, urinary system disorderRecruitingPhase 32026-07-13NCT04817618
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve StenosisVentricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorderRecruitingPhase 22026-06-23NCT05646381